| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8765100 | CEPHALON | Transmucosal effervescent |
Mar, 2019
(5 years ago) | |
| US6200604 | CEPHALON | Sublingual buccal effervescent |
Mar, 2019
(5 years ago) | |
| US6974590 | CEPHALON | Sublingual buccal effervescent |
Mar, 2019
(5 years ago) | |
| US8728441 | CEPHALON | Sublingual buccal effervescent |
Mar, 2019
(5 years ago) | |
| US8753611 | CEPHALON | Sublingual buccal effervescent |
Mar, 2019
(5 years ago) | |
| US8119158 | CEPHALON | Effervescent oral fentanyl dosage form and methods of administering fentanyl |
Dec, 2024
(8 months from now) | |
| US8092832 | CEPHALON | Generally linear effervescent oral fentanyl dosage form and methods of administering |
Dec, 2024
(8 months from now) | |
| US7862833 | CEPHALON | Effervescent oral opiate dosage forms and methods of administering opiates |
Jun, 2028
(4 years from now) | |
| US7862832 | CEPHALON | Generally linear effervescent oral fentanyl dosage form and methods of administering |
Jun, 2028
(4 years from now) | |
Fentora is owned by Cephalon.
Fentora contains Fentanyl Citrate.
Fentora has a total of 9 drug patents out of which 5 drug patents have expired.
Expired drug patents of Fentora are:
- US8765100
- US6200604
- US6974590
- US8728441
- US8753611
Fentora was authorised for market use on 25 September, 2006.
Fentora is available in tablet;buccal, sublingual dosage forms.
Fentora can be used as management of breakthrough pain in patients with cancer by buccal or sublingual administration of fentanyl, management of breakthrough pain in patients with cancer.
The generics of Fentora are possible to be released after 15 June, 2028.
Drugs and Companies using FENTANYL CITRATE ingredient
Market Authorisation Date: 25 September, 2006
Treatment: Management of breakthrough pain in patients with cancer; Management of breakthrough pain in patients with cancer by buccal or sublingual administration of fentanyl
Dosage: TABLET;BUCCAL, SUBLINGUAL
FENTORA family patents
